Fecal microbiota spores, live
As of the edition of 20 October 2026, Fecal microbiota spores, live is a drug: marketed, first approved in 2023 (US); US protection ends in 2035.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Unknown
- Brand name
- Vowst
- First approved
- 26 April 2023 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Aimmune Therapeutics
US protection
US protection ends in 2035.
The reference-product exclusivity ends in 2035. The application that gives this date is held by Aimmune Therapeutics.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Aimmune Therapeutics | Acquired holder | 2025 to now |
| Seres Therapeutics | Originator | 2023 to 2025 |